Corticotropin is a Small Molecule owned by ANI Pharmaceuticals, and is involved in 1 clinical trial, which was completed.

Corticotropin and endogenous adrenocorticotropic hormone ACTH) stimulate the adrenal cortex to secrete cortisol, corticosterone, aldosterone, and a number of weakly androgenic substances.

The revenue for Corticotropin is expected to reach a total of $3.7bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Corticotropin NPV Report.

Corticotropin is currently owned by ANI Pharmaceuticals.

Corticotropin Overview

Corticotropin (Purified Cortrophin) is a purified preparation of the adrenocorticotropic hormone (ACTH) obtained from porcine pituitary. It is formulated as solution for intramuscular or subcutaneous route of administration. Purified Cortrophin is indicated for the treatment of infantile spasms, multiple sclerosis (acute exacerbations of multiple sclerosis), rheumatic disorders (Psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis, ankylosing spondylitis), collagen diseases (systemic lupus erythematosus, systemic dermatomyositis (polymyositis)), dermatologic diseases (severe erythema multiforme, Stevens-Johnson syndrome), allergic states (Serum sickness), ophthalmic diseases (keratitis, iritis, iridocyclitis, diffuse posterior uveitis and choroiditis, optic neuritis, chorioretinitis, anterior segment inflammation), respiratory diseases (symptomatic sarcoidosis) and edematous states (proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus).

ANI Pharmaceuticals Overview

ANI Pharmaceuticals (ANI) is a specialty pharmaceutical company that develops, manufactures and markets generic and branded prescription pharmaceuticals. The company offers pharmaceuticals for central nervous system (CNS) disorders, gastrointestinal, cancer, ophthalmic, metabolic and other diseases. ANI also conducts business as a Contract Development and Manufacturing Organization (CDMO) supporting late-stage development to commercial manufacture of pharmaceutical products including coated/non-coated tablets and capsules, ointments, creams, non-sterile liquids, suspensions, and gels. It markets oncology products, complex formulations, hormones and steroids and controlled substances. The company sells products to wholesale distributors, group purchasing organizations, retail pharmacy chains and other pharmaceutical companies. ANI is headquartered in Baudette, Minnesota, the US.

The company reported revenues of (US Dollars) US$216.1 million for the fiscal year ended December 2021 (FY2021), an increase of 3.7% over FY2020. The operating loss of the company was US$39.8 million in FY2021, compared to an operating loss of US$16 million in FY2020. The net loss of the company was US$42.6 million in FY2021, compared to a net loss of US$22.6 million in FY2020. The company reported revenues of US$83.8 million for the third quarter ended September 2022, an increase of 13.5% over the previous quarter.

Quick View – Corticotropin

Report Segments
  • Innovator (Non-NME)
Drug Name
  • Corticotropin
Administration Pathway
  • Intramuscular
  • Subcutaneous
Therapeutic Areas
  • Central Nervous System
  • Dermatology
  • Genito Urinary System And Sex Hormones
  • Immunology
  • Musculoskeletal Disorders
  • Ophthalmology
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.